Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.99 -2.0%	$6.23	$3.93 ▼ $7.54	$357.17M	1.55	1.03 million shs	687,351 shs
ABOS Acumen Pharmaceuticals	$1.45 +1.8%	$1.32	$0.86 ▼ $3.36	$87.52M	0.14	331,497 shs	49,111 shs
ARCT Arcturus Therapeutics	$18.30 -6.1%	$13.57	$8.04 ▼ $25.88	$499.27M	2.26	468,964 shs	698,180 shs
CRVS Corvus Pharmaceuticals	$5.28 -2.8%	$4.26	$2.54 ▼ $10.00	$393.49M	0.42	808,623 shs	650,497 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+13.90%	+8.19%	+14.45%	+42.60%
ABOS Acumen Pharmaceuticals	0.00%	+4.41%	-5.33%	+32.71%	-44.75%
ARCT Arcturus Therapeutics	0.00%	+63.56%	+44.30%	+62.47%	-3.56%
CRVS Corvus Pharmaceuticals	0.00%	+25.99%	+27.46%	+50.00%	+32.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.5665 of 5 stars	3.5	2.0	4.5	3.8	2.5	1.3
ABOS Acumen Pharmaceuticals	3.0447 of 5 stars	3.5	5.0	0.0	1.6	1.7	0.6
ARCT Arcturus Therapeutics	2.8813 of 5 stars	3.5	2.0	0.0	3.1	2.5	0.6
CRVS Corvus Pharmaceuticals	2.895 of 5 stars	3.5	2.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.50	179.17% Upside
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	338.29% Upside
ARCT Arcturus Therapeutics	3.00	Buy	$50.00	173.22% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	184.09% Upside

Current Analyst Ratings Breakdown

Latest ABOS, ARCT, CRVS, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/15/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$19.00 ➝ $20.00
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	102.34	N/A	N/A	$1.01 per share	6.92
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$3.03 per share	N/A
ARCT Arcturus Therapeutics	$109.80M	4.53	N/A	N/A	$8.90 per share	2.06
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	$0.70	9.95	N/A	N/A	N/A	150.05%	59.86%	N/A
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	N/A
ARCT Arcturus Therapeutics	-$80.94M	-$2.23	N/A	N/A	N/A	-49.26%	-24.87%	-17.75%	11/6/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	N/A

Latest ABOS, ARCT, CRVS, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	$1.71	+$2.10	$1.71	$21.71 million	$0.40 million
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	3.91%	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
ARCT Arcturus Therapeutics	N/A	5.90	5.90
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ABOS Acumen Pharmaceuticals	71.01%
ARCT Arcturus Therapeutics	94.54%
CRVS Corvus Pharmaceuticals	46.64%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	5.40%
ABOS Acumen Pharmaceuticals	7.10%
ARCT Arcturus Therapeutics	16.60%
CRVS Corvus Pharmaceuticals	31.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.28 million	48.51 million	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	56.27 million	Optionable
ARCT Arcturus Therapeutics	180	27.16 million	23.00 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	51.19 million	Optionable

ABOS, ARCT, CRVS, and ABEO Headlines

Recent News About These Companies

Cantor Fitzgerald Brokers Cut Earnings Estimates for CRVS

August 16 at 11:29 AM | marketbeat.com

What is HC Wainwright's Forecast for CRVS Q3 Earnings?

August 16 at 8:48 AM | marketbeat.com

HC Wainwright Analysts Raise Earnings Estimates for CRVS

August 16 at 3:03 AM | americanbankingnews.com

HC Wainwright Has Bearish Estimate for CRVS FY2028 Earnings

August 15 at 10:14 AM | marketbeat.com

Research Analysts Set Expectations for CRVS FY2028 Earnings

August 14, 2025 | americanbankingnews.com

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

August 12, 2025 | seekingalpha.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded to Hold at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Raised to Hold at Wall Street Zen

August 10, 2025 | marketbeat.com

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Corvus (CRVS) Q2 Loss Beats Estimates

August 8, 2025 | aol.comA

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) top owners are retail investors with 48% stake, while 33% is held by institutions

August 5, 2025 | finance.yahoo.com

Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Cantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)

June 14, 2025 | theglobeandmail.com

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

June 11, 2025 | taiwannews.com.twT

Corvus Nicks up on Releasing Preclinical Trial Data

June 11, 2025 | baystreet.ca

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

June 4, 2025 | globenewswire.com

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

May 10, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, ARCT, CRVS, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.98 -0.15 (-2.03%)

As of 02:44 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Acumen Pharmaceuticals NASDAQ:ABOS

$1.44 +0.03 (+1.76%)

As of 02:42 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Arcturus Therapeutics NASDAQ:ARCT

$18.30 -1.18 (-6.06%)

As of 02:44 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.28 -0.15 (-2.76%)

As of 02:44 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time